Insulet Corporation (PODD)

Health Care · $10.4B market cap · SEC CIK 0001145197

Next reports on Feb 16, 2027, after the close, with analysts expecting $1.82 in earnings per share.

52-week range $126.40 to $354.88. 58% below its 52-week high and 17% above its low.

The case for PODD

• Revenue up 26.5% on the year.
• Cheap for its growth: 24.2× earnings, where 25%+ a year of growth would justify about 46×.
• Earnings per share up 80.7%.
• Has compounded revenue at 24.5% a year over five years.
• Return on equity of 17%.
• Gross margin of 72% absorbs cost shocks.

The case against

• Down 53.2% over the past year.
• Near the bottom of its 52-week range, 58% below the high. Falling prices usually have a reason; find it first.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Insulet Corporation's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Insulet Corporation says it does

Overview Insulet Corporation (“we” or the “Company”) is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod ® 5 Automated Insulin Delivery System (“Omnipod 5”), the Omnipod DASH ® Insulin Management System (“Omnipod DASH”), and the Omnipod Insulin Management System (“Classic Omnipod”). We also produce pods for Amgen for use in the Neulasta ® Onpro ® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy. Market Opportunity: Management of Diabetes Diabetes is a chronic, life-threatening disease for which there is no known cure. It is caused by the body’s inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels. Glucose, the primary source of energy for cells,…

Risk factors PODD lists in its 10-K

• We currently rely on sales of our Omnipod product platform to generate most of our revenue
• Our ability to grow our revenue depends in part on our retaining a high percentage of our customers
• If we do not effectively manage our rapid growth, our business resources may become strained and we may not be able to deliver our products in a timely manner, which could adversely affect our results of operations
• Failure to secure or retain adequate coverage or reimbursement for our products by third-party payors could adversely affect our business, revenue, financial condition, and results of operations
• If we fail to expand our relationships with intermediaries, our ability to grow our business may be materially and adversely affected
• Our non-insulin Drug Delivery product line faces challenges which, if not met, may impair its future success
• Our new product development initiatives may prove to be ineffective or not commercially successful
• Technological breakthroughs in diabetes monitoring, treatment, or prevention could render our Omnipod products obsolete or less desirable
• We may be unable to adequately protect our intellectual property rights, which could limit our ability to sell our products profitably, or at all, and cause us to incur additional costs
• Claims that our current or future products infringe or misappropriate the proprietary rights of others could adversely affect our ability to sell those products and cause us to incur additional costs
• The continuing worldwide macroeconomic and geopolitical uncertainty as well as the impact of another global pandemic may adversely affect our business and prospects
• The international nature of our business subjects us to additional business risks that may have an adverse effect on our financial condition or results of operations
• Expansion of U.S. tariffs could have a material adverse effect on our financial results
• We rely on agreements or licenses to intellectual property or other rights in order to sell our current product and commercialize new products
• Our inventory is produced and maintained in a limited number of locations, including one operated by a third party in China, and any loss could have a material adverse effect on our ability to manufacture and sell our products
• We are dependent upon third-party suppliers, making us vulnerable to supply constraints and price fluctuations, and we may not be able to obtain sufficient components or raw materials on a timely basis or at all
• Healthcare reform laws could adversely affect our revenue and financial condition
• We are subject to extensive government regulation, which could restrict the sales and marketing of our products, cause us to incur significant costs, and impact our profitability and competitiveness
• If we or our contract manufacturer fail to comply with the FDA’s quality system regulations, the manufacturing and distribution of our devices could be interrupted, and our sales and operating results could suffer
• Malfunction of our products could lead to recalls, safety alerts, or litigation and result in substantial costs and reputational damage
• We may be subject to enforcement action if we engage in improper marketing or promotion of our products
• Failure to comply with the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws could materially adversely affect our business and result in civil and/or criminal sanctions
• Our Credit Agreement imposes restrictions on us that may adversely affect our ability to operate or grow our business
• We may need to raise additional funds in the future, and these funds may not be available on acceptable terms or at all
• Our success depends on our ability to attract, motivate, and retain key personnel
• Acquisitions or investments in new businesses, products, or technologies could disrupt our business
• The price of our common stock may be volatile
• Changes in tax laws or exposures to additional tax liabilities could negatively impact our operating results

Filings

Other Health Care companies